Recombinant MVA Vaccine With 2A Peptides for Stable EBV Antigen Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EBV vaccines are inadequate in providing effective prophylaxis against Epstein-Barr virus infection and associated diseases, with monovalent gp350-based vaccines failing to reduce infection rates and multivalent approaches facing challenges in large-scale manufacturing.
Innovation Solution
A recombinant Modified Vaccinia Ankara (MVA) vector expressing multiple EBV glycoproteins (gp350, gB, gp42, and gHgL) is developed, utilizing self-cleaving 2A peptides for stable expression and co-assembly into surface complexes, enhancing immune response through a multivalent vaccine approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If monovalent gp350-based vaccines are used, then vaccine simplicity is maintained, but immunogenicity and protective efficacy are insufficient
Solution Approach 1:
The patent combines multiple EBV glycoproteins (gp350, gB, gp42, gHgL) into a single recombinant MVA vector expression system. This merging of multiple antigenic components into one vaccine platform achieves multivalent immunogenicity while maintaining a unified vaccine structure, resolving the contradiction between simplicity and efficacy.
2Reliability
If multivalent approaches are used, then immunogenicity is enhanced, but manufacturing complexity increases
Solution Approach 1:
The recombinant MVA vector serves as a universal platform that can simultaneously express multiple EBV glycoproteins through a single expression cassette system. This multi-functional vector design enables production of multivalent antigens through one manufacturing process rather than multiple separate processes, enhancing immunogenicity while simplifying manufacturing scalability.
3Reliability
If multiple EBV glycoproteins are expressed, then neutralizing activity is enhanced, but expression stability becomes challenging
Solution Approach 1:
The patent uses self-cleaving 2A peptides as intermediary elements between the multiple glycoprotein coding sequences. These 2A peptides enable autonomous cleavage and independent expression of each glycoprotein (gp350, gB, gp42, gHgL) from a polycistronic mRNA transcript, ensuring stable and balanced expression of all antigens simultaneously without compromising neutralizing activity.
Data Source
AI summary
Reconstructed Modified Vaccinia Ankara (rMVA) vectors configured to encode stable Epstein Bar Virus (EBV) glycoproteins gp42, gL, gH, gp350, and gB, compositions comprising the rMVA vectors, vaccines comprising the compositions, and methods of preventing EBV infection by administering the vaccines and eliciting an innate and humoral immune response.